Current Research Studies

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS 181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

DAS181

Phase: III
Clinicaltrials.gov ID: NCT03808922

What is the goal of the study?

This is a multi-center, randomized, double-blind, placebo-controlled Phase III study to investigate the efficacy and safety of DAS181 for the treatment of immunocompromised subjects diagnosed with lower respiratory tract infection (LRTI) due to a sialic-acid dependent respiratory virus (SAD-RV), with particular emphasis on parainfluenza (PIV).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Alpana Waghmare
Study Team Member: Jamie Costales, [email protected]